Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Commentary|Articles|July 29, 2026
Oncology Experts Review Key ASCO 2026 Data for Daraxonrasib and Other Novel Therapies in GI Cancers
Author(s)Chris Ryan
Fact checked by: Ashling Wahner
Experts reveal their top picks for gastrointestinal oncology presentations from the 2026 ASCO Annual Meeting.
Advertisement
Advertisement
While data for daraxonrasib in patients with pretreated metastatic pancreatic ductal adenocarcinoma stole the show at the
Related to this article
The FDA is reviewing data for daraxonrasib in previously treated pancreatic cancer under the Commissioner’s National Priority Voucher program.
The FDA approved gedatolisib in PIK3CA wild-type breast cancer, granted full approval to selpercatinib in RET fusion+ tumors, and more.
The FDA issued final guidances on performance status, washout periods, and laboratory values aimed at expanding oncology trial participation.
The FDA approved SimpleScreen CRC as a screening option for colorectal cancer in adults 45 years of age and older at average risk for the disease.
Sonesitatug vedotin improved overall survival in pretreated CLDN18.2-positive advanced gastric/GEJ cancers in the phase 3 CLARITY-Gastric01 trial.
The top 5 OncLive TV videos of the week cover insights in pancreatic cancer, non–small cell lung cancer, the cost and value of immunotherapy, and bladder cancer.
The FDA accepted an NDA for daraxonrasib in metastatic pancreatic cancer, approved zidesamtinib in pretreated ROS1-positive NSCLC, and more.
Advertisement
Advertisement